Supporting Clinical Decision-Making during the SARS-CoV-2 Pandemic through a Global Research Commitment: The TERAVOLT Experience

Annalisa Trama; Claudia Proto; Jennifer G. Whisenant; Valter Torri; Alessio Cortellini; Olivier Michielin; Fabrice Barlesi; Anne-Marie C. Dingemans; Jan Van Meerbeeck; Vera Pancaldi; Julien Mazieres; Ross A. Soo; Natasha B. Leighl; Solange Peters; Heather Wakelee; Leora Horn; Matthew Hellmann; Selina K. Wong; Marina Chiara Garassino; Javier Baena

doi:10.1016/j.ccell.2020.10.002

Supporting Clinical Decision-Making during the SARS-CoV-2 Pandemic through a Global Research Commitment: The TERAVOLT Experience

Annalisa Trama, Claudia Proto, Jennifer G. Whisenant, Valter Torri, Alessio Cortellini, Olivier Michielin, Fabrice Barlesi, Anne-Marie C. Dingemans, Jan Van Meerbeeck, Vera Pancaldi, Julien Mazieres, Ross A. Soo, Natasha B. Leighl, Solange Peters, Heather Wakelee, Leora Horn, Matthew Hellmann, Selina K. Wong, Marina Chiara Garassino^*, Javier Baena

^*Corresponding author for this work

GROW - Innovative Cancer Diagnostics & Therapy

Research output: Contribution to journal › Editorial › Academic › peer-review

Abstract

To understand the real impact of COVID-19 on cancer patients, an entirely new data collection effort was initiated within the Thoracic Cancers International COVID-19 Collaboration (TERAVOLT). TERAVOLT reported high mortality related to COVID-19 infection in thoracic cancer patients and identified several negative prognostic factors. In this commentary, we discuss the importance and limits of patient registries to support decision-making in thoracic cancer during the SARS-CoV-2 pandemic.

Original language	English
Pages (from-to)	602-604
Number of pages	3
Journal	Cancer Cell
Volume	38
Issue number	5
DOIs	https://doi.org/10.1016/j.ccell.2020.10.002
Publication status	Published - 9 Nov 2020

Keywords

CANCER
COVID-19
IMPACT
WUHAN

Access to Document

10.1016/j.ccell.2020.10.002Licence: Free access - publisher

Cite this

Trama, A., Proto, C., Whisenant, J. G., Torri, V., Cortellini, A., Michielin, O., Barlesi, F., Dingemans, A.-M. C., Van Meerbeeck, J., Pancaldi, V., Mazieres, J., Soo, R. A., Leighl, N. B., Peters, S., Wakelee, H., Horn, L., Hellmann, M., Wong, S. K., Garassino, M. C., & Baena, J. (2020). Supporting Clinical Decision-Making during the SARS-CoV-2 Pandemic through a Global Research Commitment: The TERAVOLT Experience. Cancer Cell, 38(5), 602-604. https://doi.org/10.1016/j.ccell.2020.10.002

@article{12985f6dd8db483fa1a9d5a2290c33ce,

title = "Supporting Clinical Decision-Making during the SARS-CoV-2 Pandemic through a Global Research Commitment: The TERAVOLT Experience",

abstract = "To understand the real impact of COVID-19 on cancer patients, an entirely new data collection effort was initiated within the Thoracic Cancers International COVID-19 Collaboration (TERAVOLT). TERAVOLT reported high mortality related to COVID-19 infection in thoracic cancer patients and identified several negative prognostic factors. In this commentary, we discuss the importance and limits of patient registries to support decision-making in thoracic cancer during the SARS-CoV-2 pandemic.",

keywords = "CANCER, COVID-19, IMPACT, WUHAN",

author = "Annalisa Trama and Claudia Proto and Whisenant, {Jennifer G.} and Valter Torri and Alessio Cortellini and Olivier Michielin and Fabrice Barlesi and Dingemans, {Anne-Marie C.} and {Van Meerbeeck}, Jan and Vera Pancaldi and Julien Mazieres and Soo, {Ross A.} and Leighl, {Natasha B.} and Solange Peters and Heather Wakelee and Leora Horn and Matthew Hellmann and Wong, {Selina K.} and Garassino, {Marina Chiara} and Javier Baena",

note = "Funding Information: C.P. received personal fees from Roche, Lilly, and Bristol-Myers Squibb and grants and travel reimbursement from Merck Sharp & Dohme, Roche, and Bristol-Myers Squibb. A.C. received grant consultancies from BMS, MSD, Astrazeneca, and Roche and speaker{\textquoteright}s fees from Astrazeneca, Astellas, and Novartis. O.M. has received grants and personal fees from Bristol Myers Squibb, Merck Sharp & Dohme, Roche, and Amgen and personal fees from Novartis. A.-M.C.D. attended advisory boards and/or provided lectures for Roche, Eli Lilly, Boehringer Ingelheim, Astra Zeneca, Pfizer, BMS, Amgen, Novartis, MSD, Takeda, and Pharmamar, received research support from BMS , AbbVie , and Amgen . R.S. received honoraria from Amgen, Astra-Zeneca, BMS, Boehringer Ingelheim, Lilly, Merck, Novartis, Pfizer, Roche, Taiho, Takeda, and Yuhan and research funding from Astra-Zeneca and Boehringer Ingelheim. N.L. received honoraria (CME lectures) from BMS, Boehringer Ingelheim, and MSD. Institutional research funding has been received from Astra Zeneca, Amgen, Array, Bayer, EMD Serono, Lilly, Roche, Guardant Health, Pfizer, Takeda, MSD. S.P. received education grants, provided consultation, attended advisory boards, and/or provided lectures for Abbvie, Amgen, AstraZeneca, Bayer, Biocartis, Bioinvent, Blueprint Medicines, Boehringer-Ingelheim, Bristol-Myers Squibb, Clovis, Daiichi Sankyo, Debiopharm, Eli Lilly, F. Hoffmann-La Roche, Foundation Medicine, Illumina, Janssen, Merck Sharp and Dohme, Merck Serono, Merrimack, Novartis, Pharma Mar, Pfizer, Regeneron, Sanofi, Seattle Genetics, Takeda, and Vaccibody, from whom she has received honoraria (all fees to institution). H.W. reports honoraria for advisory board participation from AstraZeneca, Blueprint, Xcovery, Janssen, Daiichi Sankyo, Helsinn, and Mirati; publishing fees from UpToDate; and research support paid to institution from ACEA Biosciences, Arrys Therapeutics, AztraZeneca/MedImmune, BMS, Celgene, Clovis Oncology, Exelixis, Genetech/Roche, Lilly, Merck, Novartis, Pfizer, Pharmacyclics, and Xcovery outside the submitted work. L.H. has received grants, personal fees, and travel reimbursement from Xcovery; grants and travel reimbursement from Bristol Myers Squibb; grants from Boheringer/Ingelherim; and personal fees from AstraZeneca, Roche, Incyte, Merck, Pfizer, Xcovery, EMD, Tesaro, AbbVie, Medscape, Physicians Education Resource, Research to Practice, Onclive, Amgen, and Bayer. M.D.H. received research support from Bristol-Myers Squibb; has been a compensated consultant for Merck, Bristol-Myers Squibb, AstraZeneca, Genentech/Roche, Nektar, Syndax, Mirati, Shattuck Labs, Immunai, Blueprint Medicines, Achilles, and Arcus; received travel support/honoraria from AstraZeneca, Eli Lilly, and Bristol-Myers Squibb; has options from Shattuck Labs, Immunai, and Arcus; and has a patent filed by his institution related to the use of tumor mutation burden to predict response to immunotherapy (PCT/US2015/062208), which has received licensing fees from PGDx. M.C.G. received grants, personal fees, and other financial support from Merck Sharp & Dohme, AstraZeneca, Novartis, Roche, Pfizer, Celgene; grants and other financial support from Tiziana Sciences, Clovis, GlaxoSmithKline, Spectrum, and Blueprint; personal fees and other financial support from Eli Lilly and Bristol Myers Squibb; grants from Merck and Bayer; personal fees from Boheringer, Otsuka Pharma, Incyte, Inivata, Takeda, Bayer, Sanofi, Seattle Genetics, and Daichii Sankyo; and other financial support from Merck Serono. J.B. received support for advisory/consultancy from Astra Zeneca, honoraria (self), and travel and accommodation expenses from Angelini. Funding Information: IInternational Association for the Study of Lung Cancer (IASLC) provided funding. Conceptualization, A.T. M.C.G. C.P. and J.B.; Methodology, A.T. V.T. and C.P.; Writing – Original Draft, A.T. C.P. M.C.G. L.H. H.W. J.B. and S.P.; Writing – Review & Editing, A.T. C.P. J.G.W. V.T. A.C. O.M. F.B. A.C.D. J.V.M. V.P. J.M. R.A.S. N.B.L. S.P. H.W. L.H. M.H. S.K.W. M.C.G. and J.B. Supervision, M.C.G. L.H. S.P. J.B. and H.W. Project Administration, M.C.G. L.H. S.P. H.W. F.B. A.C.D. and J.V.M. C.P. received personal fees from Roche, Lilly, and Bristol-Myers Squibb and grants and travel reimbursement from Merck Sharp & Dohme, Roche, and Bristol-Myers Squibb. A.C. received grant consultancies from BMS, MSD, Astrazeneca, and Roche and speaker's fees from Astrazeneca, Astellas, and Novartis. O.M. has received grants and personal fees from Bristol Myers Squibb, Merck Sharp & Dohme, Roche, and Amgen and personal fees from Novartis. A.-M.C.D. attended advisory boards and/or provided lectures for Roche, Eli Lilly, Boehringer Ingelheim, Astra Zeneca, Pfizer, BMS, Amgen, Novartis, MSD, Takeda, and Pharmamar, received research support from BMS, AbbVie, and Amgen. R.S. received honoraria from Amgen, Astra-Zeneca, BMS, Boehringer Ingelheim, Lilly, Merck, Novartis, Pfizer, Roche, Taiho, Takeda, and Yuhan and research funding from Astra-Zeneca and Boehringer Ingelheim. N.L. received honoraria (CME lectures) from BMS, Boehringer Ingelheim, and MSD. Institutional research funding has been received from Astra Zeneca, Amgen, Array, Bayer, EMD Serono, Lilly, Roche, Guardant Health, Pfizer, Takeda, MSD. S.P. received education grants, provided consultation, attended advisory boards, and/or provided lectures for Abbvie, Amgen, AstraZeneca, Bayer, Biocartis, Bioinvent, Blueprint Medicines, Boehringer-Ingelheim, Bristol-Myers Squibb, Clovis, Daiichi Sankyo, Debiopharm, Eli Lilly, F. Hoffmann-La Roche, Foundation Medicine, Illumina, Janssen, Merck Sharp and Dohme, Merck Serono, Merrimack, Novartis, Pharma Mar, Pfizer, Regeneron, Sanofi, Seattle Genetics, Takeda, and Vaccibody, from whom she has received honoraria (all fees to institution). H.W. reports honoraria for advisory board participation from AstraZeneca, Blueprint, Xcovery, Janssen, Daiichi Sankyo, Helsinn, and Mirati; publishing fees from UpToDate; and research support paid to institution from ACEA Biosciences, Arrys Therapeutics, AztraZeneca/MedImmune, BMS, Celgene, Clovis Oncology, Exelixis, Genetech/Roche, Lilly, Merck, Novartis, Pfizer, Pharmacyclics, and Xcovery outside the submitted work. L.H. has received grants, personal fees, and travel reimbursement from Xcovery; grants and travel reimbursement from Bristol Myers Squibb; grants from Boheringer/Ingelherim; and personal fees from AstraZeneca, Roche, Incyte, Merck, Pfizer, Xcovery, EMD, Tesaro, AbbVie, Medscape, Physicians Education Resource, Research to Practice, Onclive, Amgen, and Bayer. M.D.H. received research support from Bristol-Myers Squibb; has been a compensated consultant for Merck, Bristol-Myers Squibb, AstraZeneca, Genentech/Roche, Nektar, Syndax, Mirati, Shattuck Labs, Immunai, Blueprint Medicines, Achilles, and Arcus; received travel support/honoraria from AstraZeneca, Eli Lilly, and Bristol-Myers Squibb; has options from Shattuck Labs, Immunai, and Arcus; and has a patent filed by his institution related to the use of tumor mutation burden to predict response to immunotherapy (PCT/US2015/062208), which has received licensing fees from PGDx. M.C.G. received grants, personal fees, and other financial support from Merck Sharp & Dohme, AstraZeneca, Novartis, Roche, Pfizer, Celgene; grants and other financial support from Tiziana Sciences, Clovis, GlaxoSmithKline, Spectrum, and Blueprint; personal fees and other financial support from Eli Lilly and Bristol Myers Squibb; grants from Merck and Bayer; personal fees from Boheringer, Otsuka Pharma, Incyte, Inivata, Takeda, Bayer, Sanofi, Seattle Genetics, and Daichii Sankyo; and other financial support from Merck Serono. J.B. received support for advisory/consultancy from Astra Zeneca, honoraria (self), and travel and accommodation expenses from Angelini. Publisher Copyright: {\textcopyright} 2020 Elsevier Inc.",

year = "2020",

month = nov,

day = "9",

doi = "10.1016/j.ccell.2020.10.002",

language = "English",

volume = "38",

pages = "602--604",

journal = "Cancer Cell",

issn = "1535-6108",

publisher = "Cell Press",

number = "5",

}

Trama, A, Proto, C, Whisenant, JG, Torri, V, Cortellini, A, Michielin, O, Barlesi, F, Dingemans, A-MC, Van Meerbeeck, J, Pancaldi, V, Mazieres, J, Soo, RA, Leighl, NB, Peters, S, Wakelee, H, Horn, L, Hellmann, M, Wong, SK, Garassino, MC & Baena, J 2020, 'Supporting Clinical Decision-Making during the SARS-CoV-2 Pandemic through a Global Research Commitment: The TERAVOLT Experience', Cancer Cell, vol. 38, no. 5, pp. 602-604. https://doi.org/10.1016/j.ccell.2020.10.002

TY - JOUR

T1 - Supporting Clinical Decision-Making during the SARS-CoV-2 Pandemic through a Global Research Commitment

T2 - The TERAVOLT Experience

AU - Trama, Annalisa

AU - Proto, Claudia

AU - Whisenant, Jennifer G.

AU - Torri, Valter

AU - Cortellini, Alessio

AU - Michielin, Olivier

AU - Barlesi, Fabrice

AU - Dingemans, Anne-Marie C.

AU - Van Meerbeeck, Jan

AU - Pancaldi, Vera

AU - Mazieres, Julien

AU - Soo, Ross A.

AU - Leighl, Natasha B.

AU - Peters, Solange

AU - Wakelee, Heather

AU - Horn, Leora

AU - Hellmann, Matthew

AU - Wong, Selina K.

AU - Garassino, Marina Chiara

AU - Baena, Javier

N1 - Funding Information: C.P. received personal fees from Roche, Lilly, and Bristol-Myers Squibb and grants and travel reimbursement from Merck Sharp & Dohme, Roche, and Bristol-Myers Squibb. A.C. received grant consultancies from BMS, MSD, Astrazeneca, and Roche and speaker’s fees from Astrazeneca, Astellas, and Novartis. O.M. has received grants and personal fees from Bristol Myers Squibb, Merck Sharp & Dohme, Roche, and Amgen and personal fees from Novartis. A.-M.C.D. attended advisory boards and/or provided lectures for Roche, Eli Lilly, Boehringer Ingelheim, Astra Zeneca, Pfizer, BMS, Amgen, Novartis, MSD, Takeda, and Pharmamar, received research support from BMS , AbbVie , and Amgen . R.S. received honoraria from Amgen, Astra-Zeneca, BMS, Boehringer Ingelheim, Lilly, Merck, Novartis, Pfizer, Roche, Taiho, Takeda, and Yuhan and research funding from Astra-Zeneca and Boehringer Ingelheim. N.L. received honoraria (CME lectures) from BMS, Boehringer Ingelheim, and MSD. Institutional research funding has been received from Astra Zeneca, Amgen, Array, Bayer, EMD Serono, Lilly, Roche, Guardant Health, Pfizer, Takeda, MSD. S.P. received education grants, provided consultation, attended advisory boards, and/or provided lectures for Abbvie, Amgen, AstraZeneca, Bayer, Biocartis, Bioinvent, Blueprint Medicines, Boehringer-Ingelheim, Bristol-Myers Squibb, Clovis, Daiichi Sankyo, Debiopharm, Eli Lilly, F. Hoffmann-La Roche, Foundation Medicine, Illumina, Janssen, Merck Sharp and Dohme, Merck Serono, Merrimack, Novartis, Pharma Mar, Pfizer, Regeneron, Sanofi, Seattle Genetics, Takeda, and Vaccibody, from whom she has received honoraria (all fees to institution). H.W. reports honoraria for advisory board participation from AstraZeneca, Blueprint, Xcovery, Janssen, Daiichi Sankyo, Helsinn, and Mirati; publishing fees from UpToDate; and research support paid to institution from ACEA Biosciences, Arrys Therapeutics, AztraZeneca/MedImmune, BMS, Celgene, Clovis Oncology, Exelixis, Genetech/Roche, Lilly, Merck, Novartis, Pfizer, Pharmacyclics, and Xcovery outside the submitted work. L.H. has received grants, personal fees, and travel reimbursement from Xcovery; grants and travel reimbursement from Bristol Myers Squibb; grants from Boheringer/Ingelherim; and personal fees from AstraZeneca, Roche, Incyte, Merck, Pfizer, Xcovery, EMD, Tesaro, AbbVie, Medscape, Physicians Education Resource, Research to Practice, Onclive, Amgen, and Bayer. M.D.H. received research support from Bristol-Myers Squibb; has been a compensated consultant for Merck, Bristol-Myers Squibb, AstraZeneca, Genentech/Roche, Nektar, Syndax, Mirati, Shattuck Labs, Immunai, Blueprint Medicines, Achilles, and Arcus; received travel support/honoraria from AstraZeneca, Eli Lilly, and Bristol-Myers Squibb; has options from Shattuck Labs, Immunai, and Arcus; and has a patent filed by his institution related to the use of tumor mutation burden to predict response to immunotherapy (PCT/US2015/062208), which has received licensing fees from PGDx. M.C.G. received grants, personal fees, and other financial support from Merck Sharp & Dohme, AstraZeneca, Novartis, Roche, Pfizer, Celgene; grants and other financial support from Tiziana Sciences, Clovis, GlaxoSmithKline, Spectrum, and Blueprint; personal fees and other financial support from Eli Lilly and Bristol Myers Squibb; grants from Merck and Bayer; personal fees from Boheringer, Otsuka Pharma, Incyte, Inivata, Takeda, Bayer, Sanofi, Seattle Genetics, and Daichii Sankyo; and other financial support from Merck Serono. J.B. received support for advisory/consultancy from Astra Zeneca, honoraria (self), and travel and accommodation expenses from Angelini. Funding Information: IInternational Association for the Study of Lung Cancer (IASLC) provided funding. Conceptualization, A.T. M.C.G. C.P. and J.B.; Methodology, A.T. V.T. and C.P.; Writing – Original Draft, A.T. C.P. M.C.G. L.H. H.W. J.B. and S.P.; Writing – Review & Editing, A.T. C.P. J.G.W. V.T. A.C. O.M. F.B. A.C.D. J.V.M. V.P. J.M. R.A.S. N.B.L. S.P. H.W. L.H. M.H. S.K.W. M.C.G. and J.B. Supervision, M.C.G. L.H. S.P. J.B. and H.W. Project Administration, M.C.G. L.H. S.P. H.W. F.B. A.C.D. and J.V.M. C.P. received personal fees from Roche, Lilly, and Bristol-Myers Squibb and grants and travel reimbursement from Merck Sharp & Dohme, Roche, and Bristol-Myers Squibb. A.C. received grant consultancies from BMS, MSD, Astrazeneca, and Roche and speaker's fees from Astrazeneca, Astellas, and Novartis. O.M. has received grants and personal fees from Bristol Myers Squibb, Merck Sharp & Dohme, Roche, and Amgen and personal fees from Novartis. A.-M.C.D. attended advisory boards and/or provided lectures for Roche, Eli Lilly, Boehringer Ingelheim, Astra Zeneca, Pfizer, BMS, Amgen, Novartis, MSD, Takeda, and Pharmamar, received research support from BMS, AbbVie, and Amgen. R.S. received honoraria from Amgen, Astra-Zeneca, BMS, Boehringer Ingelheim, Lilly, Merck, Novartis, Pfizer, Roche, Taiho, Takeda, and Yuhan and research funding from Astra-Zeneca and Boehringer Ingelheim. N.L. received honoraria (CME lectures) from BMS, Boehringer Ingelheim, and MSD. Institutional research funding has been received from Astra Zeneca, Amgen, Array, Bayer, EMD Serono, Lilly, Roche, Guardant Health, Pfizer, Takeda, MSD. S.P. received education grants, provided consultation, attended advisory boards, and/or provided lectures for Abbvie, Amgen, AstraZeneca, Bayer, Biocartis, Bioinvent, Blueprint Medicines, Boehringer-Ingelheim, Bristol-Myers Squibb, Clovis, Daiichi Sankyo, Debiopharm, Eli Lilly, F. Hoffmann-La Roche, Foundation Medicine, Illumina, Janssen, Merck Sharp and Dohme, Merck Serono, Merrimack, Novartis, Pharma Mar, Pfizer, Regeneron, Sanofi, Seattle Genetics, Takeda, and Vaccibody, from whom she has received honoraria (all fees to institution). H.W. reports honoraria for advisory board participation from AstraZeneca, Blueprint, Xcovery, Janssen, Daiichi Sankyo, Helsinn, and Mirati; publishing fees from UpToDate; and research support paid to institution from ACEA Biosciences, Arrys Therapeutics, AztraZeneca/MedImmune, BMS, Celgene, Clovis Oncology, Exelixis, Genetech/Roche, Lilly, Merck, Novartis, Pfizer, Pharmacyclics, and Xcovery outside the submitted work. L.H. has received grants, personal fees, and travel reimbursement from Xcovery; grants and travel reimbursement from Bristol Myers Squibb; grants from Boheringer/Ingelherim; and personal fees from AstraZeneca, Roche, Incyte, Merck, Pfizer, Xcovery, EMD, Tesaro, AbbVie, Medscape, Physicians Education Resource, Research to Practice, Onclive, Amgen, and Bayer. M.D.H. received research support from Bristol-Myers Squibb; has been a compensated consultant for Merck, Bristol-Myers Squibb, AstraZeneca, Genentech/Roche, Nektar, Syndax, Mirati, Shattuck Labs, Immunai, Blueprint Medicines, Achilles, and Arcus; received travel support/honoraria from AstraZeneca, Eli Lilly, and Bristol-Myers Squibb; has options from Shattuck Labs, Immunai, and Arcus; and has a patent filed by his institution related to the use of tumor mutation burden to predict response to immunotherapy (PCT/US2015/062208), which has received licensing fees from PGDx. M.C.G. received grants, personal fees, and other financial support from Merck Sharp & Dohme, AstraZeneca, Novartis, Roche, Pfizer, Celgene; grants and other financial support from Tiziana Sciences, Clovis, GlaxoSmithKline, Spectrum, and Blueprint; personal fees and other financial support from Eli Lilly and Bristol Myers Squibb; grants from Merck and Bayer; personal fees from Boheringer, Otsuka Pharma, Incyte, Inivata, Takeda, Bayer, Sanofi, Seattle Genetics, and Daichii Sankyo; and other financial support from Merck Serono. J.B. received support for advisory/consultancy from Astra Zeneca, honoraria (self), and travel and accommodation expenses from Angelini. Publisher Copyright: © 2020 Elsevier Inc.

PY - 2020/11/9

Y1 - 2020/11/9

N2 - To understand the real impact of COVID-19 on cancer patients, an entirely new data collection effort was initiated within the Thoracic Cancers International COVID-19 Collaboration (TERAVOLT). TERAVOLT reported high mortality related to COVID-19 infection in thoracic cancer patients and identified several negative prognostic factors. In this commentary, we discuss the importance and limits of patient registries to support decision-making in thoracic cancer during the SARS-CoV-2 pandemic.

AB - To understand the real impact of COVID-19 on cancer patients, an entirely new data collection effort was initiated within the Thoracic Cancers International COVID-19 Collaboration (TERAVOLT). TERAVOLT reported high mortality related to COVID-19 infection in thoracic cancer patients and identified several negative prognostic factors. In this commentary, we discuss the importance and limits of patient registries to support decision-making in thoracic cancer during the SARS-CoV-2 pandemic.

KW - CANCER

KW - COVID-19

KW - IMPACT

KW - WUHAN

U2 - 10.1016/j.ccell.2020.10.002

DO - 10.1016/j.ccell.2020.10.002

M3 - Editorial

C2 - 33091381

SN - 1535-6108

VL - 38

SP - 602

EP - 604

JO - Cancer Cell

JF - Cancer Cell

IS - 5

ER -

Supporting Clinical Decision-Making during the SARS-CoV-2 Pandemic through a Global Research Commitment: The TERAVOLT Experience

Abstract

Keywords

Access to Document

Fingerprint

Cite this